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Background: Experimental findings have suggested that human cytomegalovirus 
(HCMV) infection of tumor cells may exert oncomodulatory effects that enhance 
tumor malignancy. However, controversial findings have been published on the 
presence of HCMV in malignant tumors. Here, we present the first study that 
systematically investigates HCMV infection in human nervous system tumors by 
highly sensitive immunohistochemistry in correlation with the HCMV sero-status of 
the patients. 
Methods: Immunohistochemical and qPCR-based methods to detect different HCMV 
antigens and genomic HCMV DNA were optimized prior to the investigation of 
pathological samples. Moreover, the pathological results were matched with the 
HCMV sero-status of the patients.  
Results: HCMV immediate early, late, and pp65 antigens could be detected in single 
cells from HCMV strain Hi91-infected UKF-NB-4 neuroblastoma cells after 1:1024 
dilution with non-infected UKF-NB-4 cells. Genomic HCMV DNA could be detected in 
copy numbers as low as 430 copies /ml. However, we did not detect HCMV in tumors 
from a cohort of 123 glioblastoma, medulloblastoma, or neuroblastoma patients. 
Notably, we detected non-specifically positive staining in tumor tissues of HCMV 
sero-positive and –negative glioblastoma patients. The HCMV sero-status of 67 
glioblastoma patients matched to the general epidemiological prevalence data for 
western countries (72% of female and 57% of male glioblastoma patients were 
HCMV-sero-positive). Median survival was not significantly different in HCMV sero-





Conclusions: The prevalence of HCMV-infected tumor cells may be much lower 
than previously reported based on ‘highly sensitive’ detection methods.  







Human cytomegalovirus (HCMV), a member of the herpes virus family, persists after 
primary (normally non-recognized) infection life-long in the body. The sero-
prevalence ranges from about 50 up to 100 % within a population. Higher prevalence 
levels are detected in females than in males. In addition a lower socio-economic 
status is associated with increased HCMV seroprevalence 1, 2. HCMV is a major 
pathogen in immunocompromised individuals. Although HCMV reactivates with 
varying frequency resulting in detectable virus levels in the blood and virus shedding, 
HCMV disease is an extremely rare event in immuno-competent individuals 3. During 
critical illness of immunocompetent patients, HCMV reactivation may be associated 
with prolonged hospitalisation and death 4. For decades, it has been speculated 
whether HCMV may play a role in the course of various cancer diseases 5, 6. 
Experimental evidence suggested that HCMV may cause “oncomodulatory” effects, 
i.e. that it may infect established cancer (or other tumor-associated) cells and 
enhance cancer malignancy despite not being a tumor virus with proven 
transformation potential 5, 7. In 2002, the idea of HCMV-induced oncomodulation was 
strongly supported by a clinical study that reported on the detection of HCMV 
proteins and oligonucleotides in a very high percentage of gliomas 8. This was 
followed by further studies reporting on the detection of HCMV in a high percentage 
of cancer tissues from different entities including colorectal cancer, prostate cancer, 
medulloblastoma, and neuroblastoma 9, 10, 11, 12, 13. However, other groups are 
sceptical and do not find HCMV in high fractions of tumors 14, 15, 16, 17, 18, 19. 
Interestingly, a study that correlates the HCMV sero-status with the detection of 





systematic study on the detection of HCMV by immunohistochemistry and qPCR in 
tissues from patients with nervous system tumors including a sub-group of 
glioblastoma patients for which we performed a combined analysis of HCMV sero-






Material and methods  
Patient data 
In total, 200 paraffin embedded tissue samples from 123 patients suffering from 
tumors of the nervous system including neuroblastomas (n=12), medulloblastomas 
(n=20) WHO grade IV and glioblastomas WHO grade IV (n=91) were investigated in 
our study. Additionally, normal brain tissue from autopsy cases and histologically 
normal appearing brain tissue surrounding tumor samples were studied. Tissue 
samples from patients with confirmed HCMV encephalitis served as positive controls 
for HCMV infection. The samples were obtained from the tissue bank of the Edinger 
Institute (Neurological Institute), Frankfurt, Germany. Tissue samples were fixed in 
4% buffered formalin (Roth, Karlsruhe, Germany) and embedded in paraffin. The 
histopathological diagnoses were performed according to the WHO. The use of 
patient material was approved by the local ethics committee (GS-04/09 and GS-
249/11).  
 
Assessment of HCMV sero-status 
Anti-HCMV IgG, IgM and IgA antibody screening was performed with the Architect 
2000SR (Abbott Diagnostics, Wiesbaden, Germany) according to the manufacturers´ 
instructions. While the detection of HCMV-IgG antibodies demonstrates the HCMV-
sero-positivity, the detection of IgM and / or IgG antibodies is an indication for a 







Formalin fixed, paraffin embedded sections (3µm) were subjected to 
immunohistochemistry using the following antibodies: a mouse antibody directed 
against the early nuclear, non-structural DNA-binding p52 HCMV protein (43 kDa; 
IgG1; clone CCH2; dilution: 1:500), a mouse antibody directed against the 
immediate-early HCMV antigen (76 kDa; IgG2a; clone DDG9; dilution 1:500; both 
Dako, Glostrup, Denmark), a mouse antibody directed against the HCMV pp65 
antigen (IgG1; clone 26; dilution 1:200; Leica, Wetzlar, Germany), and a mouse 
antibody directed against HCMV immediate-early antigen (IEA) (IgG1; clone 
MCA2147; dilution 1:50; Serotec, Oxford, UK). In addition, the anti-HCMV pp65 and 
anti HCMV IEA antibodies were used at dilutions of 1:20 and 1:5. Tissue labeling for 
all antigens was performed using the DiscoveryXT immunohistochemistry system 
(Ventana, Strasbourg, France). After de-paraffinization, the conditioning heat pre-
treatment with TE buffer was performed for either 36 min (clone CCH2 and DDG9, 
Dako) or 52 min (clone 26, Leica and clone MCA2147, Serotec) followed by a 4 min 
blocking step using inhibitor D (Ventana, Strasbourg, France). The primary antibodies 
were applied for 32 min at 37°C followed by one drop of Universal Secondary 
Antibody (Ventana) for another 32 min at 37°C. Then, an avidin-biotin blocker was 
applied to the samples for 4 min. For diaminobenzidine (DAB) visualization, the 
sections were incubated with one drop of I-View SA-HRP for 16 min and followed by 
incubation with DAB/H2O2 for additional 8 min. All sections were finally incubated with 
a copper enhancer (Ventana) for 4 min, then washed, counterstained with 







DNA was extracted from 12 neuroblastomas and 10 glioblastomas using standard 
protocols. HCMV real time PCR was performed using 10 µl of the extracted DNA as 
previously described 20. As positive controls, a series of 4 samples with diluted 
HCMV titres (430000 HCMV copies per ml (cs/ml), 43000 cs/ml, 4300 cs/ml and 430 
cs/ml) derived HCMV strain Hi91-infected human foreskin fibroblasts and a sample of 
cerebellar tissue from a patient with HCMV encephalitis were included. Water was 
used as negative control. GAPDH was used as housekeeping gene 21.  
 
Cell culture 
UKF-NB-4 cells, derived from bone marrow metastases of a patient with MYCN-
amplified stage IV neuroblastoma, were grown at 37°C in Iscove`s modified 
Dulbecco`s medium (IMDM) supplemented with 10 % heat-inactivated fetal calf 
serum (FCS), 100 IU/mL of penicillin, and 100µg/mL streptomycin 22. The following 
established glioma cell lines were tested: LN18, U138, U87, LN428, D247, T98G, 
LN319, LNT229, A172, U251 and U373 were kindly provided by Dr. N. de Tribolet 
(University Hospital, Lausanne, Switzerland). The adherent human glioma cell lines 
were grown in Dulbecco’s modified Eagle medium (DMEM, Gibco Invitrogen, 
Darmstadt, Germany) supplemented with 10% FCS (Provitro, Berlin, Germany) and 
1% penicillin/streptomycin (P/S) (Sigma Aldrich, Steinheim, Germany). All cells were 
grown in an incubator atmosphere of 5% CO2 at 37°C (Heraeus, Thermo Scientific, 
Dreieich, Germany). Daoy medulloblastoma cells were a gift from T. Pietsch (Bonn, 
Germany). Cells were centrifuged, fixed in 4% buffered formalin (Roth), embedded in 







Virus culture was performed as described previously 22. Stocks of HCMV strain Hi91 
were prepared in human foreskin fibroblasts maintained in minimal essential medium 
(MEM) with 4 % FCS. Virus titers were determined by plaque titration. UKF-NB-4 
cells were infected at a multiplicity of infection (MOI) of 2. 72h post-infection, the 
HCMV-infected UKF-NB-4 cells were diluted with non-infected UKF-NB-4 cells in 
ratios of 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, and 1:128 and forwarded to paraffin 
embedding and immunohistochemical analysis or qPCR analysis. 
 
Statistical analyses 
The association of patient survival with the HCMV sero-status was assessed by 
Kaplan-Meier analysis. Statistical significance levels were determined by log-rank 
and Wilcoxon test. The association of sero-status and (i) sex as well as Karnofsky 
performance score (KPS) was tested using the likelihood-ratio test, (ii) age by 
Student's t-test and (iii) location of lesion by non-parametric Wilcoxon test. A 
significance level of alpha = 0.05 was selected for all tests. Statistical analysis was 
performed using JMP 8.0.1 software (SAS, Cary, NC, USA). Graphics were prepared 







Immunohistochemical and qPCR-based methods detect HCMV in human 
neuroblastoma cells with similar sensitivity 
Human neuroblastoma cells (UKF-NB-4) were infected with HCMV Hi91 at MOI 2, 
centrifuged, and paraffin-embedded for immunohistochemical analyses. 
Approximately 40% of HCMV-infected neuroblastoma cells stained positively for 
HCMV-IEA (Figure 1A). Subsequently, infected cells were diluted at a ratio of 1:1 to 
1:1024 with non-infected UKF-NB-4 cells finally showing only single HCMV-IEA-
positive cells as assessed by immunohistochemistry (Figure 1B-G). Cerebellar tissue 
from a patient with HCMV encephalitis served as positive control (Figure 1H). 
 
Lack of HCMV antigen detection by immunohistochemical analysis in tumors of the 
central nervous system 
The immunohistochemical analyses revealed negative results for the HCMV-
associated antigens pp65, early antigen or immediate-early antigen in 12/12 
neuroblastomas (Figure 2A), 20/20 medulloblastomas (Figure 2B) and 89/91 
glioblastoma samples (Figure 2C, D). Only single glioblastoma cases showed weak 
positive staining results (Figure 2E) while cerebellar tissue derived from a patient 
with HCMV encephalitis (positive control) (Figure 2F) showed the expected positive 
staining results. Additionally, established human medulloblastoma and high-grade 
glioma cells lines were negative for HCMV antigens (data not shown). To rule out 
that HCMV infection in tumors of the nervous system might be undetected due to a 
too low antibody concentration, we increased the antibody concentrations for pp65 





which are usually not used in routine diagnostic procedures. Higher concentrated 
antibodies directed against HCMV-IEA (Serotec) and pp65 (Leica) did neither led to 
positivity in former negative cases (Figure 3A-D) nor to increased staining intensity 
or frequency in positive glioblastoma cases (Figure 3E, F).  
 
Potential pitfalls in the morphological assessment of HCMV immunohistochemistry in 
human samples  
At the first glance, single cases seemed to reveal positive staining signals for all 
antibodies used in our study (Figure 4A, B). However, the staining positivity was 
largely restricted to gemistocytes, a subtype a reactive or neoplastic astrocytes that 
often cross-react in immunohistochemical analyses with various antibodies (Figure 
4B, C). Other positive signals turned out to derive from hematoidin and hemosiderin 
pigments related to old bleedings (Figure 4D, E) as well as formalin pigment (Figure 
4F) as fixation artefacts. The negative (Figure 4G) and isotype (Figure 4H) controls 
of the respective samples exhibited similar staining results thereby indicating 
unspecificity of the stainings in these specimens. Notably, high concentrations of the 
antibodies directed against HCMV antigens resulted in a positive staining that was 
interpreted as non-specific background staining because it was present in tumors 
from sero-positive as well as sero-negative patients.      
 
HCMV is undetectable in human neuroblastoma and glioblastoma specimens using 
qPCR 
The numbers of PCR cycles that were necessary to detect HCMV in tissue culture-





cycles for 430000 cs/mL, 28.97 for 43000 cs/mL, 30.95 for 4300 cs/mL and 35.51 for 
430 cs/mL). In addition, we detected HCMV (562 cs/mL) in a cerebellar tissue sample 
from a patient with HCMV encephalitis that served as positive control. However, the 
analysis of DNA extracted from patient tumor samples (12 neuroblastomas, 10 
glioblastomas) did not result in detectable virus levels. 
 
The HCMV sero-status of glioblastoma patients is not associated with patient survival 
The HCMV sero-status of 67 patients in the glioblastoma cohort was determined and 
for 61 patients clinical outcome data were available. 24/67 (36%) glioblastoma 
patients were HCMV sero-negative and 43/67 (64%) patients were sero-positive as 
indicated by the IgM and IgG status. 72% (23/32) of the female patients and 57% 
(20/35) of the male patients were HCMV sero-positive (Figure 5A). Both overall and 
gender-related epidemiological values are in accordance with previously published 
HCMV prevalence data for western countries 23. Furthermore, we determined 
whether the HCMV sero-status of patients was related to the clinical course of the 
glioblastoma disease. Median survival times were increased in HCMV sero-positive 
glioblastoma patients although the differences did not reach statistical significance 
(Figure 5B). No significant differences concerning patient age, sex, Karnofsky 
performance score (KPS), location of lesion as well as progression-free and overall 
survival were detected between HCMV sero-positive and sero-negative individuals 
(Table 1). In addition, we analysed if the anti-HCMV IgG titres correlated with 
glioblastoma patient survival. However, no significant association of anti-HCMV IgG 






There is a long-standing controversy about the question in how many tumors of the 
nervous system HCMV can be detected and whether the presence of HCMV in tumor 
tissues may be associated with enhanced malignancy 8,18. While a couple of groups 
failed to detect HCMV in a high percentage of glioblastomas by means of 
immunohistochemical methods 15, 16, others reported the expression of various 
HCMV proteins in glioblastomas by the use of optimized immunohistochemistry 
techniques 10, 24. Similar discrepancies were reported in molecular pathological 
studies showing very high percentage (16/17) of HCMV-positive brain tumors as 
assessed by classical Sanger sequencing 25, whereas highly sensitive RNA deep 
sequencing methods failed to detect relevant amounts of HCMV (p<0.05 p.p.m.) in a 
large cohort of 167 brain tumors 18. We combined nucleic acid- and protein-based 
analyses but did not detect HCMV in tumors of the nervous system (Figure 2) 
although we were able to detect low HCMV copy numbers or single HCMV-positive 
tumor cells in experimental systems by our approach (Figure 1, 3).  
The appropriate interpretation of immunohistochemical stainings may be 
disturbed by frequently encountered pigments such as hematoidin, hemosiderin, and 
formalin precipitates (Figure 4) and by unspecific staining predominantly seen in 
gemistocytic cells (Figure 3). Notably, non-specific background staining was 
observed in glioblastoma tissues from HCMV sero-positive and –negative patients. It 
is known that mainly glial cells with gemistocytic morphology frequently react in an 
unspecific manner with many antibodies. While carefully reviewing many articles that 
claim high HCMV infection rates in human tumors of the nervous system, it becomes 





results for HCMV while the vast majority of surrounding cells remained largely 
unstained 26. Since it is not clear if these gemistocytic cells are of neoplastic or 
reactive origin, only tissue-based genetic analyses such as in-situ hybridization 
techniques for amplification or deletions as well as immunohistochemical methods 
detecting tumor-specific mutated proteins may confirm the neoplastic origin of 
gemistocytic cells.  
Based on the very high fraction of HCMV positive glioblastoma tissues 
detected by studies using optimized techniques, glioblastomas might be expected to 
be overrepresented among HCMV sero-positive individuals 8, 10, 24, 27. However, 
previous studies did not detect a relationship between the HCMV sero-prevalence 
and the glioblastoma incidence 28, 29, 30. These findings are consistent with our own 
findings that HCMV infections do not appear to be overrepresented among glioma 
patients. Currently, clinical studies investigate HCMV as a target for the treatment of 
tumors of the nervous system. In one of the most recent data collections, 
glioblastoma patients who were reported to display HCMV-positive tumors and 
treated with anti-viral drugs showed unexpectedly long survival times 31. However, 
this study has severe shortcomings both in conception and realisation and most 
importantly contrasted the controlled study published by the same group 32, 33, 34. A 
most recent study suggested that a combination of autologous HCMV-specific T cells 
with chemotherapy may be beneficial in glioblastoma patients 35. However, the 
tumors were not investigated for HCMV in this study. Thus, it remains unclear 
whether the therapeutic effects may be a direct consequence of the targeting of 
HCMV-positive cancer cells or from other effects. Our results suggest the latter case 





for cancer patients that were reported by different groups 31, 35 warrant attention also 
if they do not exert their effects through the targeting of HCMV-infected cancer cells.  
Taken together our results indicate that HCMV cannot be detected in large fractions 
of human tumors of the nervous system corroborating long-standing pathological 
findings and current deep sequencing data 15, 18, 16. Notably, we ourselves had 
detected HCMV IEA by PCR in neuroblastoma tissues from 4 of 8 patients in 
previous experiments 36. In the light of our current findings it is likely that this was due 
to the invasion of HCMV-infected immune cells such as monocytes/ macrophages. In 
addition, correlation of clinico-pathological parameters with HCMV sero-status 
indicates no association of HCMV infection with development or progression of 
glioblastomas. Both diagnostics of HCMV in tumors of the nervous system and first 
clinical trials focussing on HCMV as a target for anti-tumor treatment have to be (re-
)evaluated with caution. It remains, however, unclear whether HCMV may enhance 
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Figure 1: Immunohistochemistry (IHC)- and molecular pathological-based methods 
display similar detection limits in HCMV diagnostics 
A: IHC of paraffin-embedded HCMV strain Hi91-infected UKF-NB-4 neuroblastoma 
cells showing HCMV-IEA positive nuclei in 30-40% of the cells (arrow). B: IHC of 
paraffin-embedded HCMV-infected UKF-NB-4 cells diluted with non-infected cells in 
a ratio of 1:1. C: IHC of paraffin embedded HCMV-infected UKF-NB-4 cells diluted 
with non-infected cells in a ratio of 1:4. D: IHC of paraffin embedded HCMV-infected 
UKF-NB-4 cells diluted with non-infected cells in a ratio of 1:16. E: IHC of paraffin 
embedded HCMV-infected UKF-NB-4 cells diluted with non-infected cells in a ratio of 
1:64. F: IHC of paraffin embedded HCMV-infected UKF-NB-4 cells diluted with non-
infected cells in a ratio of 1:256. G: IHC of paraffin embedded HCMV-infected UKF-
NB-4 cells diluted with non-infected cells in a ratio of 1:1024. H: Cerebellar tissue 
from a patient with HCMV encephalitis showing atypical HCMV-positive nuclei 
(arrow) of infected neurons and positive nuclei of surrounding glial cells (arrow-
heads). (Scale 100µm)   
  
Figure 2: Tumors of the nervous system are virtually negative for HCMV antigens 
A: Neuroblastoma stained with the DAKO-antibody against HCMV ea. (early antigen) 
and HCMV iea. (immediate-early antigen) showing only HCMV-negative nuclei. B: 
Human medulloblastoma stained with the DAKO antibody against HCMV ea/iea also 
being completely negative. C, D: Two different glioblastoma specimens also being 





areas. F: Specimen of a patient suffering from cerebellar HCMV encephalitis showing 
HCMV ea/iea positive nuclei of neurons and surrounding glial cells. (Scale 100µm) 
 
Figure 3: Increased anti-HCMV antibody concentrations do not lead to stronger 
staining intensities or frequencies in tumors of the nervous system neither in positive 
nor in negative cases 
Negative glioblastomas were stained for pp65 antigen (A: antibody dilution 1:200; B: 
antibody dilution 1:5) and immediate early antigen (iea) (C: antibody dilution 1:50; D 
antibody dilution 1:5) using different antibody concentrations. Slightly HCMV-positive 
glioblastomas were stained for pp65 antigen (E: antibody dilution 1:200; F: antibody 
dilution 1:5, and iea dilution (G: antibody dilution 1:50; H: antibody dilution 1:5) using 
different antibody concentrations (Scale 50µm). 
 
Figure 4: Old intra-tumoral bleedings and fixation artefacts are potential pitfalls in 
immunohistochemistry-based HCMV diagnostics 
A: Positive glioblastoma case with gemistocytic cells being positive for HCMV-pp65 
antigen and also for B: HCMV-iea (immediate early antigen). C: Same glioblastoma 
case stained without primary antibody also showing a similar positive signal 
indicating an unspecific reaction. D, E: Neuroblastoma with hematoidin artefacts 
appearing like positive tumor cells (arrows). F: Neuroblastoma with formalin pigments 
(arrow). (Scale 50µm) 
 






A: Contingency analysis of HCMV sero-status by gender. B: Kaplan Meyer survival 
analysis investigating dependence of HCMV sero-status and patient survival. P-















































































Table 1: Patient data 
 sero-positive GBM patients sero-negative GBM patients p-value 
sex (male/female) 20/23 15/9 0.207* 
median age (range) 60 (34-80) 57.5 (36-74) 0.518** 
Karnofsky performance score (KPS)  
median (range) 80 (30-100) 90 (80-100) 0.179* 
location of lesion (supra-/infratentorial) 43/0 24/0 1.000*** 
median overall survival (range) 304 (0-714) 284 (0-725) 0.362**** 
median progression-free survival (range) 242 (0-1433) 152 (9-1178) 0.397**** 
 
*Likelihood-ratio test; **Student's t-test; ***non-parametric Wilcoxon test; ****Kaplan-Meier analysis/log-rank test 
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